Cargando…

Reduced PHLPP Expression Leads to EGFR-TKI Resistance in Lung Cancer by Activating PI3K-AKT and MAPK-ERK Dual Signaling

BACKGROUND: Epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) are effective in advanced EGFR-mutation non-small cell lung cancer (NSCLC) but the magnitude of tumor regression varies, and drug resistance is unavoidable. The pleckstrin homology domain leucine-rich repeat protein...

Descripción completa

Detalles Bibliográficos
Autores principales:	Wang, Wei, Xia, Xinhang, Chen, Kuifei, Chen, Meng, Meng, Yinnan, Lv, Dongqing, Yang, Haihua
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2021
Materias:	Oncology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8217757/ https://www.ncbi.nlm.nih.gov/pubmed/34168988 http://dx.doi.org/10.3389/fonc.2021.665045

Ejemplares similares

GBP1 Facilitates Indoleamine 2,3-Dioxygenase Extracellular Secretion to Promote the Malignant Progression of Lung Cancer
por: Meng, Yinnan, et al.
Publicado: (2021)

USP46 Inhibits Cell Proliferation in Lung Cancer through PHLPP1/AKT Pathway
por: Wang, Wei, et al.
Publicado: (2020)

Emerging roles of PHLPP phosphatases in lung cancer
por: Xia, Xinhang, et al.
Publicado: (2023)

Synergistic Antitumor Effects of Anlotinib Combined with Oral 5-Fluorouracil/S-1 via Inhibiting Src/AKT Signaling Pathway in Small-Cell Lung Cancer
por: Xia, Xinhang, et al.
Publicado: (2022)

The prognostic value of circulating lymphocyte counts and ABO blood group in lung cancer stereotactic body radiation therapy: a retrospective study
por: Chen, Meng, et al.
Publicado: (2022)

High PHLPP1 expression levels predicts longer time of acquired resistance to EGFR tyrosine kinase inhibitors in patients with lung adenocarcinoma
por: Xie, Youyou, et al.
Publicado: (2017)

Efficacy and Failure Patterns of Early SBRT to the Primary Tumor in Advanced EGFR-Mutation-Positive Lung Cancer with EFGR-TKI Treatment: A Prospective, Single Arm, Phase II Study
por: Shi, Yangyang, et al.
Publicado: (2022)

IL-22 Confers EGFR-TKI Resistance in NSCLC via the AKT and ERK Signaling Pathways
por: Wang, Xiaomeng, et al.
Publicado: (2019)

Radiotherapy improves the outcomes of immunotherapy with Sintilimab in non-small-cell lung cancer: A real-world analysis
por: Li, Shuling, et al.
Publicado: (2022)

High PHLPP expression is associated with better prognosis in patients with resected lung adenocarcinoma
por: Lv, Dongqing, et al.
Publicado: (2015)

PI3K-AKT-mTOR pathway alterations in advanced NSCLC patients after progression on EGFR-TKI and clinical response to EGFR-TKI plus everolimus combination therapy
por: Fang, Wenfeng, et al.
Publicado: (2020)

Therapeutic effect of whole brain radiotherapy on advanced NSCLC between EGFR TKI-naïve and TKI-resistant
por: Zhao, Lihao, et al.
Publicado: (2019)

Phosphorylation of PI3K/Akt and MAPK/ERK in an early entry step of enterovirus 71
por: Wong, Wen-Rou, et al.
Publicado: (2005)

Anexelekto (AXL) Increases Resistance to EGFR-TKI and Activation of AKT and ERK1/2 in Non-Small Cell Lung Cancer Cells
por: Tian, Yaqiong, et al.
Publicado: (2016)

Enhanced YAP expression leads to EGFR TKI resistance in lung adenocarcinomas
por: Lee, Ting-Fang, et al.
Publicado: (2018)

PHLPP1 is a metastasis suppressor in melanoma
por: Dai, Meng, et al.
Publicado: (2018)

Effects of evodiamine on PI3K/Akt and MAPK/ERK signaling pathways in pancreatic cancer cells
por: Hong, Zhong, et al.
Publicado: (2020)

Clonorchis sinensis Granulin Promotes Malignant Transformation of Hepatocyte Through EGFR-Mediated RAS/MAPK/ERK and PI3K/Akt Signaling Pathways
por: Wang, Caiqin, et al.
Publicado: (2021)

Detection of plasma T790M mutation after the first generation EGFR-TKI resistance of non-small cell lung cancer in the real world
por: Li, Haiyan, et al.
Publicado: (2020)

The deubiquitination enzyme USP46 functions as a tumor suppressor by controlling PHLPP-dependent attenuation of Akt signaling in colon cancer
por: Li, Xin, et al.
Publicado: (2012)

The Impact of Sequence of Chemotherapy and EGFR-TKI Treatment on Different EGFR Mutation Lung Adenocarcinoma
por: Chung, Fu-Tsai, et al.
Publicado: (2015)

Combining EGFR-TKI With SAHA Overcomes EGFR-TKI-Acquired Resistance by Reducing the Protective Autophagy in Non-Small Cell Lung Cancer
por: Cao, Peijun, et al.
Publicado: (2022)

The Roles of PI3K/AKT/mTOR and MAPK/ERK Signaling Pathways in Human Pheochromocytomas
por: Du, Juan, et al.
Publicado: (2016)

EGFR-TKI Combined with Pemetrexed versus EGFR-TKI Monotherapy in Advanced EGFR-Mutated NSCLC: A Prospective, Randomized, Exploratory Study
por: Gu, Weiguang, et al.
Publicado: (2023)

Low‑dose anlotinib combined with EGFR‑TKI can be used as an alternative for EGFR‑TKI‑resistant non‑small cell lung cancer in elderly patients
por: Chen, Yi, et al.
Publicado: (2023)

Targeting TF-AKT/ERK-EGFR Pathway Suppresses the Growth of Hepatocellular Carcinoma
por: Huang, Shan-Zhou, et al.
Publicado: (2019)

Effect of EGFR-TKI retreatment following chemotherapy for advanced non-small cell lung cancer patients who underwent EGFR-TKI
por: Xia, Guo-Hao, et al.
Publicado: (2014)

Tumor-associated macrophage-derived exosomes promote EGFR-TKI resistance in non-small cell lung cancer by regulating the AKT, ERK1/2 and STAT3 signaling pathways
por: Yuan, Shiyang, et al.
Publicado: (2022)

Genistein Protects Genioglossus Myoblast Against Hypoxia-induced Injury through PI3K-Akt and ERK MAPK Pathways
por: Ding, Wanghui, et al.
Publicado: (2017)

Crosstalk Between MAPK/ERK and PI3K/AKT Signal Pathways During Brain Ischemia/Reperfusion
por: Zhou, Jing, et al.
Publicado: (2015)

Cannabidiol‐mediated RISK PI3K/AKT and MAPK/ERK pathways decreasing reperfusion myocardial damage
por: Franco‐Vadillo, Antonio, et al.
Publicado: (2021)

Inhibition of PI3K/AKT and MAPK/ERK pathways causes activation of FOXO transcription factor, leading to cell cycle arrest and apoptosis in pancreatic cancer
por: Roy, Sanjit K, et al.
Publicado: (2010)

FKBP51 plays an essential role in Akt ubiquitination that requires Hsp90 and PHLPP
por: Tufano, Martina, et al.
Publicado: (2023)

Synergistic interaction between sorafenib and gemcitabine in EGFR-TKI-sensitive and EGFR-TKI-resistant human lung cancer cell lines
por: LI, JING, et al.
Publicado: (2013)

CRLF1 promotes malignant phenotypes of papillary thyroid carcinoma by activating the MAPK/ERK and PI3K/AKT pathways
por: Yu, Shi-Tong, et al.
Publicado: (2018)

EGFR/Met association regulates EGFR TKI resistance in breast cancer
por: Mueller, Kelly L, et al.
Publicado: (2010)

Biphasic activation of PI3K/Akt and MAPK/Erk1/2 signaling pathways in bovine herpesvirus type 1 infection of MDBK cells
por: Zhu, Liqian, et al.
Publicado: (2011)

Silencing of TRIM11 suppresses the tumorigenicity of chordoma cells through improving the activity of PHLPP1/AKT
por: Wang, Bin, et al.
Publicado: (2019)

Inhibition of PHLPP1 ameliorates cardiac dysfunction via activation of the PI3K/Akt/mTOR signalling pathway in diabetic cardiomyopathy
por: Zhang, Mingjun, et al.
Publicado: (2020)

NOTCH alteration in EGFR-mutated lung adenocarcinoma leads to histological small-cell carcinoma transformation under EGFR-TKI treatment
por: Koba, Hayato, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_72gfeanti8ia1k2mapv1imhni3